392MO Recurrent patient-reported outcome (PRO)-based deterioration predicts overall survival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial

作者：M. Moehler, Marcia Cruz‐Correa, D-Y. Oh, R-H. Xu, Ken Kato, Afsaneh Barzi, FREDERICK R. BARNES, Yongsheng Xu, T. T. Sheng, Gisoo Barnes, Ţapcov Victor · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.05.408 · 被引用次数：2 · 研究领域：Gastric Cancer Management and Outcomes、Colorectal Cancer Treatments and Studies、Pancreatic and Hepatic Oncology Research